ALKERMES | ALKS - Operating Expenses


ALKERMES reported $1.86B in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
ALKERMES USD 1.86B 56.17M Sep/2026
Amgen USD 5.69B 6B Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.52B 496M Jun/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Malin Corporation EUR 1.1M 400K Dec/2024
Merck USD 10.75B 5.02B Sep/2026
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Otsuka Holdings JPY 567.81B 6.18B Sep/2026
Ovoca Bio EUR 173K 990K Dec/2025
Pfizer USD 89B 3.81B Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026